Ignite Creation Date:
2024-05-06 @ 2:44 AM
Last Modification Date:
2024-10-26 @ 11:23 AM
Study NCT ID:
NCT02117258
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2014-04-07
Brief Title:
Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma
Sponsor:
Zeria Pharmaceutical
Organization:
Zeria Pharmaceutical
Study Overview
Official Title:
Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ZIPANG Study
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ZIPANG
Brief Summary:
The primary objective of this study is to compare the efficacy of GEM plus Z-360 versus GEM plus placebo on the overall survival OS in subjects with metastatic Pancreatic Adenocarcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None